Release Date: 23-Feb-2023
For over a long period of time, immune checkpoint inhibitors have been dominating the landscape of cancer immunotherapy. CTLA-4 and PD-1/PDL-1 inhibitors have seen a lot of advancement in recent years, however, despite their positive growth, they have found to be effective for only a minority of cancer population. New generation of immune checkpoint inhibitors was required and with continuous research and development, researchers have succeeded in discovering numerous such targets among which, TIM-3 is one of the emerging immune checkpoint target protein.
Download TIM3 Inhibitors Drug Clinical Trials and Market 2028 Report:
T-cell immunoglobulin and mucin domain (TIM-3) or HAVCR2 has been linked with shorter survival in advanced stages of several tumors and have hence become an interesting target to explore. Owing to its still unexplored therapeutic potential, researchers from all over the world have started developing their novel therapies targeting TIM-3 immune checkpoint. The pharmaceutical industry as well has begun its “imperceptible” competition.
In this race of TIM-3 targeted immune checkpoint blockers, Sabatolimab by Novartis is currently in the lead. With gaining Fast Track designation from the US FDA, the drug has also demonstrated positive results from its clinical studies and has moved to its phase II studies. Along with Sabatolimab, another anti-TIM-3 monoclonal antibody Cobolimab by GSK has initiated its phase III study. Moreover, being tested as monotherapy as well in combinational approaches with other anti-cancer immunotherapeutic approaches, primarily other immune checkpoint inhibitors, the future of these two therapies looks flourishing.
It is only a matter of time once a TIM-3 immune checkpoint inhibitors enters the commercial market of cancer immunotherapy but what is anticipated that which of these will the one to gain the “first movers edge”. In this field of cancer immunotherapy, the approach of immune checkpoint inhibitors have had a dominating share but as the patent expiration dates and limitations from existing approaches progress, the need for the discovery of novel targets and therapies increases.
With the emergence of such novel treatment modalities, the adoption of TIM-3 targeted immune checkpoint inhibitors is said to be widely accepted. Moreover, with pharmaceutical companies developing and streamlining their research and development pipelines, the approach is expected to hit the market very soon. It is also foreseeable that the sales for the initial couple of months will be robust in response and market grows more adoptive towards novel strategies.
While the market of TIM-3 immune checkpoint inhibitors is expected to be dominated by Novartis of GlaxoSmithKline as their drugs remain leading the phase II clinical trials, several other promising potential players have also entered in the competition. It is given that the positional of leading pharmaceutical brands in the current competitive landscape reflects the order of market entry as well as the reach they make in the industry. Roche being one such company to have both; the position and the reach in the pharmaceutical industry have also introduced its novel TIM-3 targeting immune checkpoint blocker.
With emerging therapeutic options, there is also emerging competition. Nevertheless, as TIM-3 represents a promising therapeutic approach, the competition seems fierce and the several newcomers are believed to mark their entry in the cancer immunotherapy market. TIM-3 antagonists have advanced their reach in clinical trials, however, the pipeline is not crowded but all the agents in studies have demonstrated promising results. Some of the molecules in clinical trials include: Sym023, MGB453, LY3321367, BMS986258, SHR1702 and several others.
This report aims to provide highlight the competitive landscape of emerging TIM-3 targeted immune checkpoint inhibitors market as well as decrying various strategies adopted by several multinational pharmaceutical players in order to gain an edge in the commercial market. Moreover, the report also provides knowledge about the current research and development being conducted against developing TIM-3 antagonists and which drug has the most anticipated arrival. Additional, our report predicts the growth of the first approved TIM-3 immune checkpoint inhibitor over the forecast period while discussing the market drivers and challenges as well as the future opportunities that may arise in this emerging market.